頁籤選單縮合
題名 | 紅麴加上益生菌對降血脂作用之評估(2-2)=The Cholesterol-Lowering Effect of LipoCol Forte Combimed Lactobacillus Casei (2-2) |
---|---|
作 者 | 李建瑩; | 書刊名 | 中醫藥年報 |
卷期 | 光碟版1:3 2012.10[民101.10] |
頁次 | 頁130-157 |
專輯 | 中藥機轉及療效 |
分類號 | 413.4 |
關鍵詞 | 紅麴; 益生菌; 抗發炎; 降血脂; Monascaceae; Lactobacillus casei; Anti-inflammation; Hyperlipidemia; |
語文 | 中文(Chinese) |
中文摘要 | 研究目的: 探討紅麴(一種 HMG-CoA還原酶抑制劑)在血脂異常與血脂正常的患者以紅麴治療後,對血漿中生化指標的影響,包含 Fibrinogen、platelet aggregation function test、Homocysteine、Adiponectin濃度、發炎指數 hs-CRP、免疫反應 (TNF-α)、Leptin濃度及骨代謝生化指標之相關性。 研究方法: 受試者於第 0、4、8、12週回診抽血四次,共保存 240管 stock serum本年度將第一年留存的研究用 stock serum,進行下列生化機轉及免疫檢驗:1.凝血功能試驗: Fibrinogen、platelet aggregation function test、Homocysteine、2.免疫及發炎試驗:hs-CRP、TNF-α、monocyte chmoprotein-1 (MCP-1)、Adiponectin、leptin及 3.骨代謝生化指標:骨形成 (bone formation)-血清骨鈣化素(osteocalcin, OC)、骨吸收(bone resorption):carboxyterminal cross-linking telopeptide of bone collagen (CTX)。 結果與討論: 本研究共納入 60位受試者,並隨機分派於治療組(n = 30)與控制組(n = 30)。經過 12週後,完成全部試驗程序 (completed study)者,治療組為 25位,控制組為 24位。故本年度將第一年完成全部試驗程序的 49位病人留存研究用 stock serum,進行生化機轉及免疫檢驗。 研究顯示紅麴加上益生菌(Monascaceae + Lactobacillus casei)與紅麴加上安慰劑(Monascaceae + Placebo)比較,在第 8週發現 Osteocalcin與 Fibrinogen的改變, p值分別為 p=0.084與 p=0.094,表示紅麴加入益生菌 Lactobacillus casei後對 Osteocalcin與 Fibrinogen的改變較單獨使用紅麴較明顯,雖未達統計上差異,但有改變的趨勢。 Adiponectin、 Plasma leptin、 Homocysteine、 Fibrinogen、 C-Telopeptide、 Osteocalcin、 Tumor necrosis factor-alpha(TNF-α)、 Monocyte chemoattractant protein-1(MCP-1)的改變可在各別 Monascaceae + Lactobacillus casei組別或 Monascaceae + Placebo組別出現有統計上的差異,但 collagen and epinephrine (Col/Epi)凝血時間延長只在 Monascaceae + Placebo一組出現有意義的改變,而 Monascaceae + Lactobacillus casei一組並無出現,顯示加入益生菌 Lactobacillus casei反而抵銷掉紅麴抗凝血功能。 |
英文摘要 | Aim: To investigate the mechanism of LipoCol Forte (red yeast rice) and Lactobacillus casei in patients with hyperlipidemia. Method: Sixty patients with hyperlipidemia were enrolled and randomized equally to group A (Monascaceae + Lactobacillus casei) or group B (Monascaceae + Placebo) for 8 weeks, followed by extension follow at week 12. Forty-nine patients completed the study. Serum samples were collected at baseline, week 4 and 8 to test for adiponectin, leptin, homocysteine, osteocalcin, C-Telopeptide, hs-CRP, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1) by ELISA kits, fribrinogen and Platlet aggregation time measured by collagen and epinephrine (Col/Epi) method. Results & Discussion: Sixty patients with hyperlipidemia were randomized and 49 patients completed this study. At week 8, group A (Monascaceae + Lactobacillus casei) had a trend of higher serum osteocalcin (p=0.084) and fibrinogen (p=0.094), as compared to group B (Monascaceae + placebo), although not statistically significant. Both groups showed significant change of adiponectin, leptin, homocysteine, fibrinogen, C-Telopeptide, osteocalcin, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1) after treatment, as compared with baseline. No statistical significance was found in serum level of adiponectin, leptin、homocysteine, C-Telopeptide, hs-CRP, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1) between groups. Platlet aggregation time measured by collagen and epinephrine (Col/Epi) increased in group B, but not group A, indicating Lactobacillus casei might diminish anti-coagulation effect of Monascaceae. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。